scholarly journals Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis: A Multicenter Real-Life Experience

2020 ◽  
Vol 30 (3) ◽  
pp. 201-204 ◽  
Author(s):  
E Nettis ◽  
◽  
L Bonzano ◽  
V Patella ◽  
A Detoraki ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life

Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy

2021 ◽  
Author(s):  
Luca Stingeni ◽  
Katharina Hansel ◽  
Elettra Antonelli ◽  
Giacomo Dal Bello ◽  
Cataldo Patruno ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life

scholarly journals Efficacy and Safety of Biologic Agents in Chronic Urticaria, Asthma and Atopic Dermatitis – A Real-life Experience

2020 ◽  
Vol 14 (1) ◽  
pp. 99-106
Author(s):  
Mohamed Abuzakouk ◽  
Omar K.H.A. Ghorab ◽  
Ali S. Wahla ◽  
Zaid Zoumot ◽  
Mohsen Nasir ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Urticaria ◽  
Test Score ◽  
Life Experience ◽  
Real Life ◽  
Biologic Agents ◽  
Atopic Asthma ◽  
P Value ◽  
Control Test ◽  
The Mean

Introduction: Several biologic agents have been approved for the treatment of asthma, chronic urticaria and atopic dermatitis. These therapeutic agents are especially useful for patients with severe or refractory symptoms. We present the real-life experience of four of the commonly used biologic agents in the United Arab Emirates. Methods: In this retrospective observational study, we reviewed the demographic, clinical, laboratory and treatment parameters for all patients treated with biologic agents. Results: 270 patients received biologics at our centre between May 2015 and December 2019 with a median age of 36.5 years. Omalizumab was the most prescribed agent (n=183, 67.8%) followed by dupilumab (n=54, 20%), benralizumab (n=22, 8.1%) and mepolizumab (n=11, 4.1%). Urticaria was the commonest treatment indication (n=148, 55%) followed by asthma (n=105, 39%) and atopic dermatitis (n=13, 5%). All chronic urticaria patients were treated with omalizumab and showed improvement in the mean urticaria control test score from 6.7±4.47 to 12.02±4.17, with a p-value of 0.001. Dupilumab was found to be the most commonly prescribed drug for asthma (37%), followed by omalizumab (32%), benralizumab (21%) and mepolizumab (10%). The mean Asthma control test score for all asthmatics combined increased from 17.06 ± 5.4 to 19.44 ± 5.6, with p-value 0.0012 with treatment; FeNO reduced from 60.02 ± 45.74 to 29.11 ± 27.92, with p-value 0.001 and mean FEV1 improved from 2.38L ± 0.8 to 2.67L ± 0.78, with p-value 0.045. Only 4 patients in the entire cohort reported adverse events. Conclusion: Our study demonstrated that biological agents are a safe and effective treatment for atopic asthma, chronic urticaria and atopic dermatitis.

scholarly journals Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID ‐19 pandemic: A single‐center real‐life experience

2020 ◽  
Vol 33 (4) ◽  
Author(s):  
Mariateresa Rossi ◽  
Chiara Rovati ◽  
Mariachiara Arisi ◽  
Simone Soglia ◽  
Piergiacomo Calzavara‐Pinton
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Single Center

Use of nintedanib for the treatment of idiopathic pulmonary fibrosis: multi-centre real life experience in Germany

Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
F Bonella ◽  
M Kreuter ◽  
L Hagmeyer ◽  
C Neurohr ◽  
K Milger ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Life Experience ◽  
Real Life
Sign in / Sign up

Export Citation Format

Share Document